Payment overview · 2025
General Payments
$176.27
10 reported records · 7 companies
Healthcare provider profile · identity verified
Brian Scott Brooks, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · HAWTHORNE, FL · NPI 1962401554
Verified facts
What the public records show
CMS Open Payments records show Brian Scott Brooks, PA received $176.27 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.71 | 19.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.53 | 19.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.18 | 18.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.16 | 13.7% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $18.56 | 10.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.92 | 9.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.21 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $176.27 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 191 | 62 |
| Gabapentin | Gabapentin | 150 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 141 | 47 |
| Lisinopril | Lisinopril | 141 | 48 |
| Losartan Potassium | Losartan Potassium | 126 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 40 |
| Metformin Hcl | Metformin Hcl | 114 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 41 |
| Famotidine | Famotidine | 96 | 38 |
| Omeprazole | Omeprazole | 93 | 37 |
| Trazodone Hcl | Trazodone Hcl | 80 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 24 |
| Simvastatin | Simvastatin | 72 | 22 |
| Furosemide | Furosemide | 67 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 23 |
| Meloxicam | Meloxicam | 62 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 22 |
| Glipizide | Glipizide | 57 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 16 |
| Ibuprofen | Ibuprofen | 54 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 13 |
| Sertraline Hcl | Sertraline Hcl | 50 | 16 |
| Metformin Hcl Er | Metformin Hcl | 47 | 18 |
| Mupirocin | Mupirocin | 47 | 17 |
| Prednisone | Prednisone | 46 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | 11 |
| Azithromycin | Azithromycin | 43 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | 13 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 14 |
| Potassium Chloride | Potassium Chloride | 34 | 13 |
| Ozempic | Semaglutide | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 14 |
| Amoxicillin | Amoxicillin | 30 | 19 |
| Eliquis | Apixaban | 30 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 11 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 11 |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $176.27 · 10 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, OTEZLA, PREVNAR 20, QULIPTA, QUTENZA, REPATHA, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error